Health & BiotechFDA approval

FDA approves bladder-cancer regimen with survival benefit around surgery

“Durvalumab and enfortumab vedotin offer a new option for adults unable to receive or declining cisplatin, but bladder removal remains part of treatment.”

How this story was made

This story was written with AI assistance from U.S. Food and Drug Administration’s regulatory notice. Its figures and quotations were checked against their sources, and Digitalage Desk reviewed and approved it before publication. It is published under the name of Peter Michaels, Editor.

Not investment advice.

AI-generated illustration of an anatomical bladder model beside an IV drip bag and a scalpel on a green surgical cloth
AI-generated illustration

The U.S. Food and Drug Administration has approved a treatment for muscle-invasive bladder cancer that improved survival in a late-stage trial, offering another option for adults who cannot receive or have declined cisplatin-based chemotherapy.

The November 13 approval covers durvalumab, sold as Imfinzi, combined with enfortumab vedotin before bladder-removal surgery. Patients then receive durvalumab alone afterward.

Primary sourceU.S. Food and Drug Administration: “FDA approves durvalumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer”

What the trial found

In the relevant comparison within the three-group VOLGA trial, 233 patients were assigned to the new regimen and 229 to the control group. The control called for bladder-removal surgery, with or without locally approved postoperative treatment, according to AstraZeneca’s detailed account filed with the SEC.

The study’s published abstract in the New England Journal of Medicine estimated that 78.4% of patients assigned to the regimen were alive at two years, compared with 69.4% in the control group. Estimated event-free survival was 63.5% versus 45.1%.

Event-free survival is broader than avoiding a recurrence. In VOLGA, an event could include cancer progression or recurrence, failure to undergo surgery while residual cancer remained, or death. The two-year estimates therefore should not be read as cure rates.

AstraZeneca funded the study. Its results were published October 24; the subsequent FDA decision authorizes the regimen for the specified patient group. The comparison does not establish that it works better than other drug combinations.

Benefits come with substantial risks

The journal abstract reported severe or worse adverse events, classified as grade 3 or higher, in 71.1% of patients receiving the regimen, compared with 50.2% in the control group. Those figures include events of any cause and should not all be attributed to the medicines. Treatment-related events at that severity occurred in 30.7% of the regimen group.

The FDA lists rash, fatigue, diarrhea and peripheral neuropathy among common adverse reactions, and warns about immune-mediated reactions with durvalumab. The agency’s announcement says median overall survival had not yet been reached in either comparison group, leaving the longer-term survival picture incomplete.

The planned course consists of three cycles of both drugs before surgery, followed by up to nine cycles of durvalumab afterward. Postoperative treatment can end sooner if the cancer recurs or side effects become unacceptable.

End of story